A differential release of matrix metalloproteinases 9 and 2 during coronary artery bypass grafting and off-pump coronary artery bypass surgery

Journal of Thoracic and Cardiovascular Surgery

Volumn 137, Issue 5, 2009, Pages 1218-1224

  Sokal, Adam ^a   Zembala, Michal ^a   Radomski, Anna ^b   Kocher, Alfred ^c   Pacholewicz, Jerzy ^a   Los, Joanna ^a   Jedrzejczyk, Ewa ^a   Zembala, Marian ^a   Radomski, Marek ^b  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

^b TRINITY COLLEGE DUBLIN   (Ireland)

^c INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE A; GELATINASE B; MYELOPEROXIDASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY BYPASS SURGERY; CORONARY ARTERY DISEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME RELEASE; FEMALE; HEART MUSCLE BIOPSY; HUMAN; HUMAN TISSUE; INFLAMMATION; INTERMETHOD COMPARISON; MALE; OFF PUMP CORONARY SURGERY; PRIORITY JOURNAL; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; ZYMOGRAPHY;

AGED; BIOLOGICAL MARKERS; COHORT STUDIES; CORONARY ARTERY BYPASS; CORONARY ARTERY BYPASS, OFF-PUMP; CORONARY DISEASE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PROBABILITY; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 64649096212     PISSN: 00225223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jtcvs.2008.11.004     Document Type: Article

References (36)

1. Biondi-Zoccai G.G., Abbate A., Agostoni P., Parisi Q., Turri M., Anselmi M., et al. Stenting versus surgical bypass grafting for coronary artery disease: systematic overview and meta-analysis of randomized trials. Ital Heart J 4 (2003) 271-280
2. Kestin A.S., Valeri C.R., Khuri S.F., Loscalzo J., Ellis P.A., MacGregor H., et al. The platelet function defect of cardiopulmonary bypass. Blood 82 (1993) 107-117
3. Rinder C.S., Gaal D., Student L.A., and Smith B.R. Platelet-leukocyte activation and modulation of adhesion receptors in pediatric patients with congenital heart disease undergoing cardiopulmonary bypass. J Thorac Cardiovasc Surg 107 (1994) 280-288
4. Goldstein D.J., Beauford R.B., Luk B., Karanam R., Prendergast T., Sardari F., et al. Multivessel off-pump revascularization in patients with severe left ventricular dysfunction. Eur J Cardiothorac Surg 24 (2003) 72-80
5. Medina C., and Radomski M. Role of matrix metalloproteinases in intestinal inflammation. J Pharmacol Exp Ther 318 (2006) 933-938
6. Coker M.L., Doscher M.A., Thomas C.V., Galis Z.S., and Spinale F.G. Matrix metalloproteinase synthesis and expression in isolated LV myocyte preparations. Am J Physiol Heart Circ Physiol 277 (1999) H777-H787
7. Nataatmadja M., West J., and West M. Overexpression of transforming growth factor-beta is associated with increased hyaluronan content and impairment of repair in Marfan syndrome aortic aneurysm. Circulation 114 suppl (2006) I371-I377
8. Montero I., Orbe J., Varo N., Beloqui O., Monreal J.I., Rodriguez J.A., et al. C-reactive protein induces matrix metalloproteinase-1 and -10 in human endothelial cells: implications for clinical and subclinical atherosclerosis. J Am Coll Cardiol 47 (2006) 1369-1378
9. Galley H.F., Macaulay G.D., and Webster N.R. Matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-1 and tumour necrosis factor a release during cardiopulmonary bypass. Anesthesia 57 (2002) 659-662
10. Wan S., LeClers J.L., and Vincent J.L. Inflammatory response to cardiopulmonary bypass: mechanisms involved and possible therapeutic strategies. Chest 112 (1997) 676-692
11. Joffs C., Gunasinghe H.R., Multani M.M., Dorman B.H., Kratz J.M., Crumbley III A.J., et al. Cardiopulmonary bypass induces the synthesis and release of matrix metalloproteinases. Ann Thorac Surg 71 (2001) 1518-1523
12. Lalu M.M., Pasini E., Schulze C.J., Ferrari-Vivaldi M., Ferrari-Vivaldi G., Bachetti T., et al. Ischaemia-reperfusion injury activates matrix metalloproteinases in the human heart. Eur Heart J 26 (2005) 27-35
13. Sawicki G., Salas E., Murat J., Miszta-Lane H., and Radomski M.W. Release of gelatinase A during platelet activation mediates aggregation. Nature 386 (1997) 616-619
14. Mayers I., Hurst T., Puttagunta L., Radomski A., Mycyk T., Sawicki G., et al. Cardiac surgery increases the activity of matrix metalloproteinases and nitric oxide synthase in human hearts. J Thorac Cardiovasc Surg 122 (2001) 746-752
15. Radomski A., Jurasz P., Sanders E.J., Overall C.M., Bigg H.F., Edwards D.R., et al. Identification, regulation and role of tissue inhibitor of metalloproteinases-4 (TIMP-4) in human platelets. Br J Pharmacol 137 (2002) 1330-1338
16. Lin T.C., Li C.Y., Tsai C.S., Ku C.H., Wu C.T., Wong C.S., et al. Neutrophil-mediated secretion and activation of matrix metalloproteinase-9 during cardiac surgery with cardiopulmonary bypass. Anesth Analg 100 (2005) 1554-1560
17. Schulze C.J., Wang W., Suarez-Pinzon W.L., Sawicka J., Sawicki G., and Schulz R. Imbalance between tissue inhibitor of metalloproteinase-4 and matrix metalloproteinases during acute myocardial ischemia-reperfusion injury. Circulation 107 (2003) 2487-2492
18. Cheung P.Y., Sawicki G., Wozniak M., Wang W., Radomski M.W., and Schulz R. Matrix metalloproteinase-2 contributes to ischemia-reperfusion injury in the heart. Circulation 101 (2000) 1833-1839
19. Santos-Martinez M.J., Medina C., Jurasz P., and Radomski M.W. Role of metalloproteinases in platelet function. Thromb Res 121 (2008) 535-542
20. Jeyabalan A., Novak J., Doty K.D., Matthews J., Fisher M.C., Kerchner L.J., et al. Vascular matrix metalloproteinase-9 mediates the inhibition of myogenic reactivity in small arteries isolated from rats after short-term administration of relaxin. Endocrinology 148 (2007) 189-197
21. Fernandez-Patron C., Martinez-Cuesta M.A., Salas E., Sawicki G., Wozniak M., Radomski M.W., et al. Differential regulation of platelet aggregation by matrix metalloproteinases-9 and -2. Thromb Haemost 82 (1999) 1730-1735
22. Santos-Martinez M.J., Medina C., Jurasz P., and Radomski M.W. Role of metalloproteinases in platelet function. Thromb Res 121 (2008) 535-542
23. Kelly D., Cockerill G., Ng L.L., Thompson M., Khan S., Samani N.J., et al. Plasma matrix metalloproteinase-9 and left ventricular remodelling after acute myocardial infarction in man: a prospective cohort study. Eur Heart J 28 (2007) 711-718
24. Roach G.W., Kanchuger M., Mangano C.M., Newman M., Nussmeier N., Wolman R., et al. Adverse cerebral outcomes after coronary bypass surgery. N Engl J Med 335 (1996) 1857-1863
25. Gill R., and Murkin J.M. Neuropsychologic dysfunction after cardiac surgery: what is the problem?. J Cardiothorac Vasc Anesth 10 (1996) 91-98
26. Herrmann M., Ebert A.D., Galazky I., Wunderlich M.T., Kunz W.S., and Huth C. Neurobehavioral outcome prediction after cardiac surgery: role of neurobiochemical markers of damage to neuronal and glial brain tissue. Stroke 31 (2000) 645-650
27. Clark R.E., Brillman J., Davis D.A., Lovell M.R., Price T.R.P., and Magovern G.J. Microemboli during coronary artery bypass grafting: genesis and effect on outcome. J Thorac Cardiovasc Surg 109 (1995) 249-258
28. Rosenberg G.A., Estrada E.Y., and Dencoff J.E. Matrix metalloproteinases and TIMPs are associated with blood-brain barrier opening after reperfusion in rat brain. Stroke 29 (1998) 2189-2195
29. Krizanac-Bengez L., Hossain M., Fazio V., Mayberg M., and Janigro D. Loss of flow induces leukocyte-mediated MMP/TIMP imbalance in dynamic in vitro blood-brain barrier model: role of pro-inflammatory cytokines. Am J Physiol Cell Physiol 291 (2006) C740-C749
30. Romanic A.M., White R.F., Arleth A.J., Ohlstein E.H., and Barone F.C. Matrix metalloproteinase expression increases after cerebral focal ischemia in rats: inhibition of matrix metalloproteinase-9 reduces infarct size. Stroke 29 (1998) 1020-1030
31. Yang Y., Estrada E.Y., Thompson J.F., Liu W., and Rosenberg G.A. Matrix metalloproteinase-mediated disruption of tight junction proteins in cerebral vessels is reversed by synthetic matrix metalloproteinase inhibitor in focal ischemia in rat. J Cereb Blood Flow Metab 27 (2007) 697-709
32. Gidday J.M., Gasche Y.G., Copin J.C., Shah A.R., Perez R.S., Shapiro S.D., et al. Leukocyte-derived matrix metalloproteinase-9 mediates blood-brain barrier breakdown and is proinflammatory after transient focal cerebral ischemia. Am J Physiol Heart Circ Physiol 289 (2005) H558-H568
33. Sawicki G., Leon H., Sawicka J., Sariahmetoglu M., Schulze C.J., Scott P.G., et al. Degradation of myosin light chain in isolated rat hearts subjected to ischemia-reperfusion injury: a new intracellular target for Matrix Metalloproteinase-2. Circulation 112 (2005) 544-552
34. Birkedal-Hansen H., Moore W.G., Bodden M.K., Windsor L.J., Birkedal-Hansen B., DeCarlo A., et al. Matrix metalloproteinases: a review. Crit Rev Oral Biol Med 4 (1993) 197-250
35. Fabunmi R.P., Baker A.H., Murray E.J., Booth R.F., and Newby A.C. Divergent regulation by growth factors and cytokines of 95 kDa and 72 kDa gelatinases and tissue inhibitors or metalloproteinases-1, -2, and -3 in rabbit aortic smooth muscle cells. Biochem J 315 (1996) 335-342
36. Opdenakker G., Van den Steen P.E., Dubois B., Nelissen I., Van Coillie E., Masure S., et al. Gelatinase B functions as regulator and effector in leukocyte biology. J Leukoc Biol 69 (2001) 851-859